1. Home
  2. SUNS vs ENTA Comparison

SUNS vs ENTA Comparison

Compare SUNS & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUNS
  • ENTA
  • Stock Information
  • Founded
  • SUNS 2023
  • ENTA 1995
  • Country
  • SUNS United States
  • ENTA United States
  • Employees
  • SUNS N/A
  • ENTA N/A
  • Industry
  • SUNS Real Estate Investment Trusts
  • ENTA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SUNS Real Estate
  • ENTA Health Care
  • Exchange
  • SUNS Nasdaq
  • ENTA Nasdaq
  • Market Cap
  • SUNS 148.0M
  • ENTA 164.6M
  • IPO Year
  • SUNS N/A
  • ENTA 2013
  • Fundamental
  • Price
  • SUNS $9.94
  • ENTA $11.30
  • Analyst Decision
  • SUNS Strong Buy
  • ENTA Strong Buy
  • Analyst Count
  • SUNS 3
  • ENTA 6
  • Target Price
  • SUNS $13.58
  • ENTA $20.83
  • AVG Volume (30 Days)
  • SUNS 73.0K
  • ENTA 1.5M
  • Earning Date
  • SUNS 11-13-2025
  • ENTA 11-24-2025
  • Dividend Yield
  • SUNS 12.06%
  • ENTA N/A
  • EPS Growth
  • SUNS N/A
  • ENTA N/A
  • EPS
  • SUNS 1.04
  • ENTA N/A
  • Revenue
  • SUNS $16,359,932.00
  • ENTA $64,806,000.00
  • Revenue This Year
  • SUNS $183.25
  • ENTA $0.07
  • Revenue Next Year
  • SUNS $62.46
  • ENTA N/A
  • P/E Ratio
  • SUNS $9.54
  • ENTA N/A
  • Revenue Growth
  • SUNS 1342.10
  • ENTA N/A
  • 52 Week Low
  • SUNS $7.80
  • ENTA $4.09
  • 52 Week High
  • SUNS $15.74
  • ENTA $15.34
  • Technical
  • Relative Strength Index (RSI)
  • SUNS 34.63
  • ENTA 58.20
  • Support Level
  • SUNS $9.77
  • ENTA $9.91
  • Resistance Level
  • SUNS $10.29
  • ENTA $11.59
  • Average True Range (ATR)
  • SUNS 0.31
  • ENTA 1.50
  • MACD
  • SUNS -0.14
  • ENTA 0.21
  • Stochastic Oscillator
  • SUNS 6.20
  • ENTA 49.58

About SUNS Sunrise Realty Trust Inc. Common Stock

Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Share on Social Networks: